• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

High-dose fluoroquinolones in short-course regimens for treatment of MDR-TB: the way forward?

作者信息

Yew Wing-Wai, Nuermberger Eric

出版信息

Int J Tuberc Lung Dis. 2013 Jul;17(7):853-4. doi: 10.5588/ijtld.13.0301.

DOI:10.5588/ijtld.13.0301
PMID:23743304
Abstract
摘要

相似文献

1
High-dose fluoroquinolones in short-course regimens for treatment of MDR-TB: the way forward?短程治疗耐多药结核病的高剂量氟喹诺酮类药物：未来之路？
Int J Tuberc Lung Dis. 2013 Jul;17(7):853-4. doi: 10.5588/ijtld.13.0301.
2
Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone.氟喹诺酮类药物高度耐药导致耐多药结核病较短疗程的局限性。
Emerg Infect Dis. 2019 Sep;25(9):1760-1762. doi: 10.3201/eid2509.190105.
3
[Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].[含氟喹诺酮类抗结核药物的短期治疗方案用于耐利福平肺结核的疗效与安全性研究]
Zhonghua Liu Xing Bing Xue Za Zhi. 2009 Feb;30(2):179-83.
4
Fluoroquinolones and dairy intake: dogma or evidence? Considerations on the short-course regimen for children.氟喹诺酮类药物与乳制品摄入：教条还是证据？关于儿童短程治疗方案的思考。
Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1316-1317. doi: 10.5588/ijtld.17.0462.
5
Treatment of multidrug-resistant tuberculosis: should you try this at home?耐多药结核病的治疗：你应该在家尝试这个吗？
Am J Respir Crit Care Med. 2004 May 15;169(10):1082-3. doi: 10.1164/rccm.2403003.
6
Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis.用于治疗和预防耐多药结核病的氟喹诺酮类药物。
Int J Tuberc Lung Dis. 2016 Dec 1;20(12):42-47. doi: 10.5588/ijtld.16.0117.
7
Current prospects for the fluoroquinolones as first-line tuberculosis therapy.氟喹诺酮类药物作为一线抗结核治疗的现状。
Antimicrob Agents Chemother. 2011 Dec;55(12):5421-9. doi: 10.1128/AAC.00695-11. Epub 2011 Aug 29.
8
[Treatment of drug resistant destructive pulmonary tuberculosis: gemifloxacin and other fluoroquinolones clinical efficiency and tolerance at the end of initial phase of treatment].[耐多药毁损型肺结核的治疗：吉米沙星及其他氟喹诺酮类药物在治疗初始阶段结束时的临床疗效及耐受性]
Lik Sprava. 2013 Dec(8):55-63.
9
An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.一种用于评估左氧氟沙星对耐多药结核病治疗方案贡献的优化背景方案设计：一项随机对照试验的研究方案
Trials. 2017 Nov 25;18(1):563. doi: 10.1186/s13063-017-2292-x.
10
Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.氟喹诺酮类药物在治疗氧氟沙星耐药、莫西沙星敏感的多药耐药结核病中的作用有限。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01784-17. Print 2018 Feb.

引用本文的文献

1
A Moxifloxacin-based Regimen for the Treatment of Recurrent, Drug-sensitive Pulmonary Tuberculosis: An Open-label, Randomized, Controlled Trial.莫西沙星方案治疗复治、药敏肺结核的疗效：一项开放标签、随机、对照试验。
Clin Infect Dis. 2020 Jan 1;70(1):90-98. doi: 10.1093/cid/ciz152.
2
Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.高剂量抗结核药物治疗结核病：机制和结果。
Ann Clin Microbiol Antimicrob. 2017 Oct 3;16(1):67. doi: 10.1186/s12941-017-0239-4.
3
Preclinical Efficacy Testing of New Drug Candidates.
新药候选物的临床前疗效测试。
Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0034-2017.
4
The Race Is On To Shorten the Turnaround Time for Diagnosis of Multidrug-Resistant Tuberculosis.缩短耐多药结核病诊断周转时间的竞赛已经开始。
J Clin Microbiol. 2015 Dec;53(12):3715-8. doi: 10.1128/JCM.02398-15. Epub 2015 Sep 16.
5
Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges.耐多药和广泛耐药结核病：当前概念和未来挑战的综述。
Clin Med (Lond). 2014 Jun;14(3):279-85. doi: 10.7861/clinmedicine.14-3-279.